CD274 and cancer: Increased baseline PD-L1 tended to be associated with clinical benefit, suggesting that sitravatinib resensitizes at least a subset of tumors to CPI and is in line with previous data suggesting that CPIs have increased activity in PD-L1-high cancers.1,43,45 Given the complexity of the TME, further research, including randomized trials, is needed to accurately select biomarkers and patients for immunotherapy and immunotherapy-based regimens.46